Loading...
•
Dec 31, 2021
Pacira Q4 2021 Earnings Report
Pacira had a pivotal year due to the acquisition of Flexion Therapeutics combined with record EXPAREL sales, entering 2022 in the strongest financial position in the company’s history.
Key Takeaways
Pacira BioSciences reported a 22% increase in total revenues for Q4 2021, reaching $159.2 million compared to $131.0 million in Q4 2020. EXPAREL net product sales increased by 12% to $139.9 million. The company experienced a GAAP net loss of $5.1 million, or $0.12 per share, but adjusted EBITDA increased by 61% to $69.3 million.
Total revenues increased by 22% to $159.2 million compared to Q4 2020.
EXPAREL net product sales increased by 12% to $139.9 million compared to Q4 2020.
ZILRETTA net product sales were $12.7 million after the acquisition of Flexion Therapeutics in November 2021.
Adjusted EBITDA increased by 61% to $69.3 million compared to Q4 2020.
Revenue by Segment
Forward Guidance
Pacira is providing full-year 2022 operating expense guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...